Pacira BioSciences, Inc. PCRX Business Segments
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Total net product sales by Product | |||||
| Bupivacaine liposome injectable suspension | $6.91M-5.6% | $7.32M+119% | $3.34M-48.4% | $6.48M+79.5% | |
| EXPAREL | $575.13M+4.8% | $548.96M+2.0% | $538.12M+0.2% | $536.9M+6.0% | |
| iovera° | $24.18M+6.0% | $22.81M+15.9% | $19.69M+29.0% | $15.26M-5.6% | |
| ZILRETTA | $116.63M-1.2% | $118.09M+6.3% | $111.1M+5.3% | $105.52M+732% | |
| Percentage of long lived assets by Geography | |||||
| Germany | 9%— | —— | —— | —— | |
| U.K | 8%— | —— | —— | —— | |
| U.S | 83%— | —— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Pacira BioSciences, Inc. break its business down?
- Pacira BioSciences, Inc. (PCRX) reports total net product sales by product across 4 parts — Bupivacaine liposome injectable suspension, EXPAREL, iovera° and ZILRETTA. Each is extracted from the segment footnotes and tracked over time.
- Where does Pacira BioSciences, Inc.'s segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Pacira BioSciences, Inc.'s SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
